Synthetic Bone Graft Substitutes - Medical Devices Pipeline Assessment, 2020

Summary

The publisher's Medical Devices sector report, “Synthetic Bone Graft Substitutes - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Synthetic Bone Graft Substitutes pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Synthetic bone graft substitutes are used as substitutes to autograft and allograft bone. Major types of synthetic bone substitutes include calcium sulfate, calcium phosphate, tricalcium phosphate (TCP), and coralline hydroxyapatite.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Synthetic Bone Graft Substitutes under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Synthetic Bone Graft Substitutes and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Synthetic Bone Graft Substitutes under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction

2.1 Synthetic Bone Graft Substitutes Overview

3 Products under Development

3.1 Synthetic Bone Graft Substitutes - Pipeline Products by Stage of Development
3.2 Synthetic Bone Graft Substitutes - Pipeline Products by Territory
3.3 Synthetic Bone Graft Substitutes - Pipeline Products by Regulatory Path
3.4 Synthetic Bone Graft Substitutes - Pipeline Products by Estimated Approval Date
3.5 Synthetic Bone Graft Substitutes - Ongoing Clinical Trials

4 Synthetic Bone Graft Substitutes - Pipeline Products under Development by Companies

4.1 Synthetic Bone Graft Substitutes Companies - Pipeline Products by Stage of Development
4.2 Synthetic Bone Graft Substitutes - Pipeline Products by Stage of Development

5 Synthetic Bone Graft Substitutes Companies and Product Overview

5.1 Agenta Biotechnologies Inc (Inactive) Company Overview
5.1.1 Agenta Biotechnologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.2 Amend Surgical, Inc. Company Overview
5.2.1 Amend Surgical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.3 Anika Therapeutics Inc Company Overview
5.3.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.4 Baxter International Inc Company Overview
5.4.1 Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview
5.5 Berkeley Advanced Biomaterials Inc Company Overview
5.5.1 Berkeley Advanced Biomaterials Inc Pipeline Products & Ongoing Clinical Trials Overview
5.6 Bio2 Technologies Inc Company Overview
5.6.1 Bio2 Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.7 BioGend Therapeutics Co Ltd Company Overview
5.7.1 BioGend Therapeutics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.8 Biomatlante SA Company Overview
5.8.1 Biomatlante SA Pipeline Products & Ongoing Clinical Trials Overview
5.9 Biorez Inc Company Overview
5.9.1 Biorez Inc Pipeline Products & Ongoing Clinical Trials Overview
5.10 Bone Solutions Inc Company Overview
5.10.1 Bone Solutions Inc Pipeline Products & Ongoing Clinical Trials Overview
5.11 BoneGrafix, Inc. Company Overview
5.11.1 BoneGrafix, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.12 BoneSupport AB Company Overview
5.12.1 BoneSupport AB Pipeline Products & Ongoing Clinical Trials Overview
5.13 Calcitec, Inc. Company Overview
5.13.1 Calcitec, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.14 Dimension Inx LLC Company Overview
5.14.1 Dimension Inx LLC Pipeline Products & Ongoing Clinical Trials Overview
5.15 DSM Biomedical BV Company Overview
5.15.1 DSM Biomedical BV Pipeline Products & Ongoing Clinical Trials Overview
5.16 Eskisehir Osmangazi University Company Overview
5.16.1 Eskisehir Osmangazi University Pipeline Products & Ongoing Clinical Trials Overview
5.17 EternoGen Aesthetics LLC Company Overview
5.17.1 EternoGen Aesthetics LLC Pipeline Products & Ongoing Clinical Trials Overview
5.18 Graftys SA Company Overview
5.18.1 Graftys SA Pipeline Products & Ongoing Clinical Trials Overview
5.19 Innovoss Inc. (Inactive) Company Overview
5.19.1 Innovoss Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.20 IRCCS San Raffaele Hospital Company Overview
5.20.1 IRCCS San Raffaele Hospital Pipeline Products & Ongoing Clinical Trials Overview
5.21 Isto Biologics Company Overview
5.21.1 Isto Biologics Pipeline Products & Ongoing Clinical Trials Overview
5.22 King's College London Company Overview
5.22.1 King's College London Pipeline Products & Ongoing Clinical Trials Overview
5.23 Maxigen Biotech Inc Company Overview
5.23.1 Maxigen Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview
5.24 National Center of Innovation for Biomaterials in Orthopaedic Research Company Overview
5.24.1 National Center of Innovation for Biomaterials in Orthopaedic Research Pipeline Products & Ongoing Clinical Trials Overview
5.25 National University of Science and Technology MiSiS Company Overview
5.25.1 National University of Science and Technology MiSiS Pipeline Products & Ongoing Clinical Trials Overview
5.26 OrthoMedex LLC Company Overview
5.26.1 OrthoMedex LLC Pipeline Products & Ongoing Clinical Trials Overview
5.27 PolyPid Ltd Company Overview
5.27.1 PolyPid Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.28 Polytechnic University of Catalonia Company Overview
5.28.1 Polytechnic University of Catalonia Pipeline Products & Ongoing Clinical Trials Overview
5.29 Promimic AB Company Overview
5.29.1 Promimic AB Pipeline Products & Ongoing Clinical Trials Overview
5.30 ReCaPP Company Overview
5.30.1 ReCaPP Pipeline Products & Ongoing Clinical Trials Overview
5.31 RepRegen Ltd. (Inactive) Company Overview
5.31.1 RepRegen Ltd. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.32 Revivicor Inc Company Overview
5.32.1 Revivicor Inc Pipeline Products & Ongoing Clinical Trials Overview
5.33 Sanara MedTech Inc Company Overview
5.33.1 Sanara MedTech Inc Pipeline Products & Ongoing Clinical Trials Overview
5.34 Scil Technology GmbH Company Overview
5.34.1 Scil Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.35 SDIP Innovations Pty Ltd Company Overview
5.35.1 SDIP Innovations Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.36 SIRAKOSS Ltd Company Overview
5.36.1 SIRAKOSS Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.37 Sofregen Medical Inc Company Overview
5.37.1 Sofregen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.38 Soteira Inc Company Overview
5.38.1 Soteira Inc Pipeline Products & Ongoing Clinical Trials Overview
5.39 SurgaColl Technologies Ltd Company Overview
5.39.1 SurgaColl Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.40 SurGenTec LLC Company Overview
5.40.1 SurGenTec LLC Pipeline Products & Ongoing Clinical Trials Overview
5.41 University of California San Diego Company Overview
5.41.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview
5.42 University of Edinburgh Company Overview
5.42.1 University of Edinburgh Pipeline Products & Ongoing Clinical Trials Overview
5.43 Wright Medical Group NV Company Overview
5.43.1 Wright Medical Group NV Pipeline Products & Ongoing Clinical Trials Overview
5.44 Xtant Medical Holdings Inc Company Overview
5.44.1 Xtant Medical Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview

6 Synthetic Bone Graft Substitutes- Recent Developments

6.1 Jul 07, 2020: New collagen supply agreement with NovaBone Products
6.2 Jun 29, 2020: DePuy Synthes renews cooperation agreement with AO Foundation to continue advancement of surgical education
6.3 May 28, 2020: Conformis announces settlement of patent dispute
6.4 Apr 08, 2020: Wright Medical Group announces virtual meeting alternative to physical attendance at Extraordinary General Meeting of Shareholders and change of time and location of meeting
6.5 Apr 08, 2020: Anika takes actions to strengthen liquidity in light of covid-19
6.6 Mar 06, 2020: Pentax Medical donates USD430,000 worth of medical devices to fight novel corona virus (2019-ncov)
6.7 Mar 02, 2020: Stryker announces new Investor Relations leader
6.8 Feb 25, 2020: Stryker announces nomination of new Director, Lisa Skeete Tatum
6.9 Feb 24, 2020: 2020 Catalyst award winner Medtronic hires Chief Inclusion and Diversity Officer
6.10 Feb 24, 2020: AbbVie announces extension of expiration date for exchange offers for Allergan notes
6.11 Feb 24, 2020: 2020 Catalyst Award Winner Medtronic hires Chief Inclusion and Diversity Officer
6.12 Feb 19, 2020: Integra LifeSciences reports fourth quarter and full-year 2019 financial results and provides 2020 financial guidance
6.13 Feb 18, 2020: Medtronic reports third quarter financial results 2020
6.14 Feb 05, 2020: Stryker expands Flower Mound regional headquarters
6.15 Feb 04, 2020: Zimmer Biomet announces fourth quarter and full-year 2019 financial results
6.16 Jan 30, 2020: Kuros reports publication of MagnetOs preclinical data demonstrating superiority to market-leading synthetic bone grafts in spinal fusion
6.17 Jan 28, 2020: aap Implantate AG: FY/19: Good fourth quarter with EUR 3.1 million revenue (+17%) results in 9% revenue growth in fiscal year 2019 - Milestones in key technologies silver coating and magnesium-based implants
6.18 Jan 28, 2020: Stryker reports 2019 results and 2020 outlook
6.19 Jan 15, 2020: MEDICREA reports 2019 annual sales
6.20 Jan 13, 2020: NuVasive announces preliminary unaudited fourth quarter and full year 2019 revenue results
6.21 Jan 13, 2020: ATEC announces preliminary 2019 revenue results and 2020 revenue outlook
6.22 Jan 12, 2020: Baxter announces preliminary net sales for the fourth-quarter and full-year 2019 and announces preliminary full-year 2020 guidance
6.23 Jan 09, 2020: Pomerantz law firm investigates claims on behalf of investors of Baxter
6.24 Jan 08, 2020: Zimmer Biomet appoints Keri P. Mattox as Senior Vice President of Investor Relations and Chief Communications Officer
6.25 Jan 08, 2020: Globus Medical reports preliminary record fourth quarter and full year sales results
6.26 Jan 02, 2020: NuVasive appoints Matthew K. Harbaugh as chief financial officer
6.27 Dec 18, 2019: Biogennix reports record year for sales
6.28 Dec 13, 2019: Globus Medical announces Board of Director addition and departure
6.29 Dec 10, 2019: Anika commences full U.S. commercial launch of TACTOSET bone repair therapy at Orthopaedic Summit 2019: Evolving Techniques
6.30 Dec 09, 2019: BoneSupport CERTiFy study on Cerament Bone Void Filler now published in the journal of bone and joint surgery
6.31 Dec 05, 2019: Ted Bird and David Gill join Bio2 Technologies Board of Directors
6.32 Dec 04, 2019: Lumeon and Medtronic partner to deliver new models of care in Europe
6.33 Dec 03, 2019: RTI Surgical accelerates business transformation with senior leadership appointments
6.34 Dec 03, 2019: Heidi DeGrazia appointed Chief Financial Officer Of N2 Biomedical
6.35 Dec 02, 2019: Rosen, a highly ranked firm, announces filing of securities class action lawsuit against Baxter International

7 Appendix

7.1 Methodology
7.2 About the Publisher
7.3 Contact
7.4 Disclaimer

List of Tables

Table 1: Synthetic Bone Graft Substitutes - Pipeline Products by Stage of Development
Table 2: Synthetic Bone Graft Substitutes - Pipeline Products by Territory
Table 3: Synthetic Bone Graft Substitutes - Pipeline Products by Regulatory Path
Table 4: Synthetic Bone Graft Substitutes - Pipeline Products by Estimated Approval Date
Table 5: Synthetic Bone Graft Substitutes - Ongoing Clinical Trials
Table 6: Synthetic Bone Graft Substitutes Companies - Pipeline Products by Stage of Development
Table 7: Synthetic Bone Graft Substitutes - Pipeline Products by Stage of Development
Table 8: Agenta Biotechnologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 9: B-247 Cranial Bone Graft Implant - Product Status
Table 10: B-247 Cranial Bone Graft Implant - Product Description
Table 11: Amend Surgical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Biomimetic Bone - Product Status
Table 13: Biomimetic Bone - Product Description
Table 14: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 15: Hyalobone - Product Status
Table 16: Hyalobone - Product Description
Table 17: Hyalofast - Product Status
Table 18: Hyalofast - Product Description
Table 19: Hyalograft C Autograft - Product Status
Table 20: Hyalograft C Autograft - Product Description
Table 21: Anika Therapeutics Inc - Ongoing Clinical Trials Overview
Table 22: Hyalofast - A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority of Hyalofast with BMAC in the Treatment of Articular Knee Cartilage Defect Lesions in Comparison to Control
Table 23: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 24: Synthetic Bone Graft - Spinal - Product Status
Table 25: Synthetic Bone Graft - Spinal - Product Description
Table 26: Berkeley Advanced Biomaterials Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 27: CPA Ceramics - Product Status
Table 28: CPA Ceramics - Product Description
Table 29: HAP Ceramics - Product Status
Table 30: HAP Ceramics - Product Description
Table 31: Bio2 Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Vitrium - Hammertoe Correction - Product Status
Table 33: Vitrium - Hammertoe Correction - Product Description
Table 34: Vitrium - Radial Osteotomy - Product Status
Table 35: Vitrium - Radial Osteotomy - Product Description
Table 36: Vitrium - Wrist Fracture Revision - Product Status
Table 37: Vitrium - Wrist Fracture Revision - Product Description
Table 38: BioGend Therapeutics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 39: OIF - Non-Union Bone Fracture - Product Status
Table 40: OIF - Non-Union Bone Fracture - Product Description
Table 41: OIF/ß-TCP - Block Form - Product Status
Table 42: OIF/ß-TCP - Block Form - Product Description
Table 43: OIF/ß-TCP - Granular Form - Product Status
Table 44: OIF/ß-TCP - Granular Form - Product Description
Table 45: Biomatlante SA Pipeline Products & Ongoing Clinical Trials Overview
Table 46: Osteoconductive Resorbable Composite - Product Status
Table 47: Osteoconductive Resorbable Composite - Product Description
Table 48: Biorez Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 49: L-C Ligament - Product Status
Table 50: L-C Ligament - Product Description

List of Figures

Figure 1: Synthetic Bone Graft Substitutes - Pipeline Products by Stage of Development
Figure 2: Synthetic Bone Graft Substitutes - Pipeline Products by Territory
Figure 3: Synthetic Bone Graft Substitutes - Pipeline Products by Regulatory Path
Figure 4: Synthetic Bone Graft Substitutes - Pipeline Products by Estimated Approval Date
Figure 5: Synthetic Bone Graft Substitutes - Ongoing Clinical Trials